Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kara Reitz"'
Autor:
Ovidiu C. Andronesi, Isabel C. Arrillaga-Romany, K. Ina Ly, Wolfgang Bogner, Eva M. Ratai, Kara Reitz, A. John Iafrate, Jorg Dietrich, Elizabeth R. Gerstner, Andrew S. Chi, Bruce R. Rosen, Patrick Y. Wen, Daniel P. Cahill, Tracy T. Batchelor
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-9 (2018)
Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1) entered recently clinical trials for treatment of gliomas. Here, the authors apply a MRS imaging method for 2HG detection and assessement of the pharmacodynamic effects of the mutant IDH1 inhibit
Externí odkaz:
https://doaj.org/article/b6420b3093174f1f828f783b189caae2
Autor:
Matthew Z. Sun, Priyanka Naik, Maxwell M Wang, Kara Reitz, Diana Babayan, Won Kim, Jia-Shu Chen
Publikováno v:
Neurosurgery. 66:310-712
Autor:
Priyanka Naik, Jingyi Jessica Li, Matthew Z. Sun, Maxwell M Wang, Won Kim, Jia-Shu Chen, Nader Pouratian, Kara Reitz, Diana Babayan
Publikováno v:
Neurosurgery, vol 89, iss 1
Author(s): Sun, Matthew Z; Babayan, Diana; Chen, Jia-Shu; Wang, Maxwell M; Naik, Priyanka K; Reitz, Kara; Li, Jingyi Jessica; Pouratian, Nader; Kim, Won | Abstract: BackgroundThe neurointensive care unit (NICU) has traditionally been the default reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f87a69ee7ba56ec64555a62193947d
https://escholarship.org/uc/item/3zr8646c
https://escholarship.org/uc/item/3zr8646c
Autor:
Fred G. Barker, Kate T. Carroll, Jasmine A T DiCesare, William T. Curry, Pamela S. Jones, Matthew J. Koch, Daniel P. Cahill, Kara Reitz, Matthew P. Frosch
Publikováno v:
Neurosurgery. 84:519-528
BACKGROUND Older age has been associated with worse outcomes in low-grade gliomas (LGGs). Given their rarity in the older population, determining optimal treatment plans and patient outcomes remains difficult. OBJECTIVE To retrospectively study LGG s
Autor:
A. John Iafrate, Ovidiu C. Andronesi, Wolfgang Bogner, Bruce R. Rosen, Eva M. Ratai, Andrew S. Chi, K. Ina Ly, Jorg Dietrich, Tracy T. Batchelor, Isabel Arrillaga-Romany, Patrick Y. Wen, Elizabeth R. Gerstner, Daniel P. Cahill, Kara Reitz
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-9 (2018)
Nature Communications
Nature Communications
Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene